Neutrophil-to-lymphocyte ratio and in-hospital mortality in patients with acute heart failure

OBJECTIVES: Previous studies have demonstrated the role of inflammation in acute heart failure. The neutrophil-to-lymphocyte ratio was found to be a useful inflammatory marker for predicting adverse outcomes. We hypothesized that an elevated neutrophil-to-lymphocyte ratio would be associated with increased mortality in acute heart failure patients. METHODS: The study cohort consisted of 167 acute heart failure patients with an ejection fractio

İleri derecede kalp yetersizliğinde tek doz ve aralıklı levosimendan infüzyonu alan hastalarda sol ventrikül performansı, biyolojik markerler ve nörohormonal aktivasyon

TEZ6956Tez (Uzmanlık) -- Çukurova Üniversitesi, Adana, 2008.Kaynakça (s.73-80) var.ix, 81 s. : res. ; 29 cm.Amaç: Bu çalışmada ileri derece kalp yetersizliği nedeniyle tek doz ve aralıklı levosimendan infüzyonu yapılan hastalarda sol ventrikül performansı, biyolojik markerler ve nörohormonal aktivasyon incelendi. Gereç ve Yöntem: Akut dekompanse ileri derece kalp yetersizliği tanısıyla hastaneye yatırılan ve sol ventrikül ejeksiyon fraksiyonu % 35 veya altında olan 29 hasta (20 erkek, 9 kadın, yaş ortalaması: 60,2 ± 7,4 yıl) çalışmaya dahil edildi. Hastalar tek doz ve aralıklı (başlangıç, 1. ay ve 3. ay) olmak üzere iki ayrı grupta incelendi.On dakikada 6 ?g/kg yükleme ve ardından 0,1 ?g/kg/dk dozunda idame 24 saatlik levosimendan infüzyonu alan hastalar, levosimendan almadan önce, aldıktan sonra 3. gün ve 6. ayda klinik, ekokardiyografik ve laboratuar (B tipi natriüretik peptit, interlökin-1 beta, interlökin-2 , interlökin-6, tümör nekroz faktör alfa) olarak değerlendirildi.Aim: The aim of the study was to investigate the effects of single and intermittent levosimendan infusion on left ventricular performance, biomarkers and neurohormonal activation in patients with acute exerbation of advanced heart failure. Methods: Twenty nine patients (20 male, 9 female, mean age 60,2 ± 7,4 years) with acute exerbation of advanced heart failure (ejection fraction ? 35 %) were included in this study. Levosimendan was initiated as a bolus of 6 ?g/kg followed by a continuous infusion of 0,1 ?g/kg/min for 24 hours in both groups who were taken intravenous single and intermittent (baseline, 1. and 3. month) treatment. Physical examination, echocardiography and biochemical tests (brain natriuretic peptide interleukin-1?, interleukin-2, interleukin-6, tumour necrosis factor-?) were performed before treatment and on the 3. day of the treatment. The last evaluation was performed on the 6. month after the baseline treatment.Bu çalışma Ç.Ü. Bilimsel Araştırma Projeleri Birimi Tarafından Desteklenmiştir. Proje No:TF2007LTP2

Thrombotic lesion of saphenous vein graft resolved by antiaggregant therapy

WOS: 000208578200007PubMed ID: 18400618

Thrombus fragmentation using iliac balloon angioplasty in a patient with massive pulmonary embolism

WOS: 000258503500014PubMed ID: 18676310

Early experience of percutaneous paravalvular leak closure using a novel Occlutech occluder

WOS: 000372767000020PubMed: 26897292Aims: Paravalvular regurgitation is an important complication of mitral valve replacement. Although surgical repair is mostly recommended, it is associated with significant morbidity. On the other hand, percutaneous closure is a less invasive alternative approach. Percutaneous approaches to treatment of paravalvular prosthetic regurgitation have emerged recently. One of them is the Occlutech Paravalvular Leak Device. The aim of this study was to evaluate early and midterm outcomes of percutaneous paravalvular leak closure utilising a novel occluder. Methods and results: Twenty-one consecutive symptomatic patients who had moderate or severe paravalvular prosthetic regurgitation on transoesophageal echocardiography were included in the study. All the patients were clinically evaluated and found inoperable for surgery. They underwent transapical repair with the Occlutech Paravalvular Leak Device. The patients were followed for 17 +/- 5 months. Attempts were made to rectify 41 defects in 21 patients with 100% success. Mean procedure time was 76140 min and fluoroscopy time was 44 +/- 37 min. Early post-procedural outcome was uneventful in all cases, with >= 1 grade reduction in regurgitation in all of the patients. There was no mortality during hospital stay. There was one case of haemothorax in one patient and one case of pneumothorax in another. Post-implantation 90-day follow-up data were obtained for 19 patients, and 12-month data were obtained for 12 patients. No deaths due to any cause, stroke or surgery for prosthetic impingement, worsening or relapse of paravalvular leak during follow-up were recorded. One patient underwent reintervention and was treated successfully with the same occluder 11 months after the index procedure. Conclusions: The novel Occlutech Paravalvular Leak Device, which was designed specifically for mitral and aortic paravalvular regurgitation, is an additional, useful tool in the device armamentarium for the treatment of PVL